CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI) Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art Review

Editorial01 July 2020

JOURNAL:Eur Heart J. Article Link

Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram

B Asatryan, L Roten, T Reichlin et al. Keywords: sudden death; arrhythmic death; electrocardiogram; CHD

ABSTRACT

The important study concerning the easy-to-use electrocardiogram (ECG) markers of sudden and/or arrhythmic death (SAD) in coronary artery disease (CAD) patients as presented by Chatterjee et al.1 is a weighty contribution to an intricate and still rather puzzling topic. They implicate that in CAD patients, contiguous Q waves, left ventricular hypertrophy (LVH), QRS duration, and JTc prolongation provide incremental predictive value beyond traditional risk factors for SAD. While this study is unique in providing easily measurable markers that improve SAD risk stratification, it also...